Type 1 and type 2 diabetes
Reading File
Finding Sources
Searching PubMed
"diabetes mellitus"[MeSH Terms] AND classification
Reading File
Reading File
Reading File
Finding Sources
Reading File
Type 1 vs Type 2 Diabetes Mellitus
Both are chronic disorders of hyperglycemia, but they differ fundamentally in cause, natural history, and treatment.
Quick comparison
| Feature | Type 1 Diabetes | Type 2 Diabetes |
|---|---|---|
| Frequency | 5-10% of diabetes cases | 90-95% of diabetes cases |
| Typical onset | Any age, but peaks in childhood/young adulthood | Increasing with age, but rising in children/adolescents with obesity |
| Pathogenesis | Autoimmune destruction of pancreatic beta cells -> absolute insulin deficiency | Insulin resistance plus progressive beta-cell dysfunction; no autoimmunity |
| Body habitus | Often normal weight | Usually overweight/obese |
| C-peptide | Very low or undetectable | Detectable (falls over time) |
| Autoantibodies | Present (GAD65, IA-2, IAA, ZnT8) in most cases | Absent |
| Ketosis risk | High - untreated patients develop diabetic ketoacidosis (DKA) | Lower, though DKA and hyperosmolar states can occur, especially under stress |
| Genetics | HLA-DR/DQ (chromosome 6) linked; triggered by an environmental event (e.g., viral infection) in genetically susceptible people | Strong familial/polygenic component; specific genes largely undefined |
| Key risk factors | Genetic susceptibility + autoimmunity + environmental trigger | Obesity (BMI ≥25, or ≥23 in Asian Americans), sedentary lifestyle, family history, age ≥45, high-risk ethnicity, PCOS, gestational diabetes history, hypertension, dyslipidemia |
| Symptoms at presentation | Usually symptomatic (polyuria, polydipsia, weight loss); can present in DKA | Often asymptomatic; frequently diagnosed on screening or after a complication develops |
| Treatment | Insulin is absolutely required (multiple daily injections or pump) | Lifestyle changes, oral agents/noninsulin injectables (e.g., metformin); insulin commonly added over time |
| Prevention | No proven prevention; disease-modifying trials ongoing | Weight loss, physical activity, and metformin/acarbose can delay or prevent onset in high-risk individuals |
(Henry's Clinical Diagnosis and Management by Laboratory Methods, p. 269-270)
Pathophysiology
Type 1 results from immune-mediated destruction of insulin-producing beta cells in the pancreatic islets. Genetic susceptibility (particularly HLA-DR/DQ haplotypes) combines with an environmental trigger - proposed to include viral infections or toxin exposure - to initiate autoimmunity. Beta-cell loss is gradual, often over months to years (the "prediabetes" phase), during which the first-phase insulin response to glucose is progressively lost. Eventually insulin secretion becomes inadequate or absent, producing hyperglycemia and, if untreated, diabetic ketoacidosis. Autoantibodies to GAD65, insulin (IAA), IA-2, and ZnT8 are markers of ongoing beta-cell destruction and are useful for prediction and diagnosis, though their absence does not exclude the diagnosis - Henry's Clinical Diagnosis and Management by Laboratory Methods, p. 268-269.
Type 2 is driven primarily by insulin resistance in peripheral tissues (muscle, liver, fat) combined with a relative, progressive insulin secretory defect. It is not autoimmune - pancreatic autoantibodies are absent, and C-peptide remains measurable, though beta-cell mass declines over time. Obesity is the dominant modifiable driver, acting through mechanisms that increase insulin resistance - Henry's Clinical Diagnosis and Management by Laboratory Methods, p. 270.
Diagnostic criteria (same lab thresholds apply to both types; ADA 2022 standards)
| Status | Fasting glucose | 2-hr OGTT glucose | HbA1c |
|---|---|---|---|
| Normal | <100 mg/dL (5.6 mmol/L) | <140 mg/dL (7.8 mmol/L) | <5.7% |
| Prediabetes | 100-125 mg/dL (5.6-6.9 mmol/L) | 140-199 mg/dL (7.8-11.0 mmol/L) | 5.7-6.4% |
| Diabetes | ≥126 mg/dL (7.0 mmol/L) | ≥200 mg/dL (11.1 mmol/L) | ≥6.5% |
Diagnosis requires two abnormal tests, or one abnormal test plus unequivocal hyperglycemia (random glucose >200 mg/dL) with classic symptoms (polyuria, polydipsia, weight loss). A single abnormal result needs confirmation on a separate sample - Goldman-Cecil Medicine, Table 210-3, p. 2472.
Distinguishing the two types clinically relies on age, body habitus, presence of autoantibodies, C-peptide level, and whether ketosis is present, though overlap exists (e.g., lean adults with autoimmune diabetes misclassified as type 2, or obese adolescents with type 1).
Complications (shared, but differ in emphasis)
Both types carry risk of the same microvascular complications (retinopathy, nephropathy, neuropathy) and macrovascular disease (coronary artery disease, stroke, peripheral arterial disease), driven mainly by degree and duration of hyperglycemia. Type 1 patients are more prone to acute DKA; type 2 patients are more prone to hyperosmolar hyperglycemic state and carry a higher baseline cardiovascular risk burden due to associated metabolic syndrome features (hypertension, dyslipidemia, obesity).
Management principles
- Type 1: Insulin replacement is mandatory from diagnosis - basal-bolus multiple daily injections or continuous subcutaneous insulin infusion (pump), often paired with continuous glucose monitoring. No oral agent substitutes for insulin.
- Type 2: Stepwise approach starting with lifestyle modification (weight loss, physical activity) plus metformin as first-line pharmacotherapy in most guidelines, escalating to additional oral agents, GLP-1 receptor agonists, SGLT2 inhibitors, or insulin as beta-cell function declines or as comorbidities (cardiovascular/renal disease) dictate agent choice.
Recent literature note
A 2025 systematic review and meta-analysis on novel diabetes subgroups (PMID: 41188395) and a 2025 systematic review on idiopathic diabetes phenotypes (PMID: 40553956) both point to increasing recognition that the classic type 1/type 2 dichotomy is a simplification - subgroups with mixed features (e.g., "type 1.5"/LADA, ketosis-prone type 2, monogenic diabetes) are increasingly characterized using antibody status, C-peptide, and genetic testing. If you want, I can go deeper into these emerging classification schemes or into any single aspect above (e.g., detailed insulin regimens, drug classes for type 2, or DKA vs HHS management).
This is a shared conversation. Sign in to Orris to start your own chat.